Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 4, 2005, Pages 305-314

  Lüke, Matthias ^a   Lüke, Christoph ^a   Hescheler, Jürgen ^a   Schneider, Toni ^a   Sickel, Werner ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SILVER; SILVER CHLORIDE;

A WAVE; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B WAVE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CROSS REACTIVITY; ELECTRORETINOGRAM; LONG TERM EXPOSURE; NONHUMAN; NUTRIENT SOLUTION; OXYGEN BLOOD LEVEL; PHOTORECEPTOR; POSTSYNAPTIC POTENTIAL; RETINA DEGENERATION; RETINA DISEASE; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ACTION POTENTIALS; ANIMALS; CATTLE; ELECTRORETINOGRAPHY; PHOSPHODIESTERASE INHIBITORS; PHOTIC STIMULATION; PIPERAZINES; RETINA;

EID: 23944443865     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.305     Document Type: Article

References (38)

1. Carson, C.C. Long-term use of sildenafil. Expert. Opin. Pharmacotherap. 4:397-405, 2003.
2. Carson, C.C. Sildenafil: A 4 year Update in the Treatment of 20 Million Erectile dysfunction Patients. Urology Rep. 4:488-496, 2003.
3. Küthe, A., Mägert, H.J., Ückert, S., et al. Gene expression of the phosphodiesterases 3A and 5A in Human Corpus Cavernosum Penis. Eur. Urol. 38:108-114, 2000.
4. Küthe, A., Wiedenroth, A., Mägert, H. J., et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Urol. 165:280-283, 2001.
5. Andersson, K.E., and Wagner, G. Physiology of penile erection. Physiol. Rev. 75:191-236, 1995.
6. Boolell, M., Allen, M.J., Ballard, S.A., et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 8:47-52, 1996.
7. Jarrow, J.P., Burnett, A.L., and Geringer, A.M. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J. Urol. 162:722-725, 1999.
8. Goldstein, I., Lue, T.F., Padma-Nathan, H., et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338:1397-1404, 1998.
9. Stryer, L. Visual excitation and recovery. J. Biol. Chem. 266:10711-10714, 1991.
10. Stryer, L. Vision: From photon to perception. Proc. Natl. Acad. Sci. 93:557-559, 1996.
11. Corbin, J.D., and Francis, S.H. Cyclic phosphodiesterase-5: Target of sildenafil. J. Biol. Chem. 274:13729-13732, 1999.
12. Corbin, J.D., and Francis, S.H. Pharamacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56:453-459, 2002.
13. Marmor, M.F., and Calif, S. Sildenafil (Viagra) and ophthalmology. Arch. Ophthalmol. 117:518-519, 1999.
14. Zrenner, E. How should Viagra-induced vision disorders, especially retinal degeneration, be evaluated? [in German] Klin. Monatsbl. Augenheilkd. 212:aA12-aA13, 1998.
15. U.S. Food and Drug Administration. Center for Drug Evaluation and Research Study 148-004 phase I investigator blind placebo-controlled evaluation of safety toleration and pharmacokinetics of sildenafil following escalation of single oral doses in healthy male volunteers. Viagra (Sildenafil): Joint Clinical Review for NDA-20-95. U.S. Food and Drug Administration, 2004. Online document at: www.fda.gov/ cder/foi/nda/98/viagra/jointclinical/APPEN_A5_ THRU_APPEN_A9_6.PDF Accessed March 1998.
16. Laties, A.M., and Fraunfelder, F.T. Ocular safety of Viagra (sildenafil citrate). Trans. Am. Ophthal. Soc. 97:115-125, 1999.
17. Jägle, H., Jägle, C., Sérey, L., et al. Visual short-term effects of Viagra®: Double-blind study in healthy young subjects. Am. J. Ophthalmol. 137:842-849, 2004.
18. Sickel, W. Retinal metabolism in dark and light. In: Handbook of Sensory Physiology Vol. VII, 2. Fuortes, M.G.F., ed. Berlin/Heidelberg/New York: Springer, 1972:667-727.
19. Hanawa, I., and Tateishi, T. The effect of aspartate on the electroretinogram of the vertebrate retina. Experientia 26:1311-1312, 1970.
20. Lüke, C., Bartz-Schmidt, K.U., Walter, P., et al. Effects of etoposide (VP16) on retinal function. J. Toxicol. Cut. Ocular. Toxicol. 18:23-32, 1999.
21. Lüke, C., Walter, P., Bartz-Schmidt, K.U., et al. Effects of antiviral agents on retinal function in vertebrate retina. Advances in Ocular Toxicology. Green, K., Edelhauser, H.F., Hackett, R.B., eds. New York: Plenum Press, 1997:107-112.
22. Shiells, R.A., and Falk, G. Glutamate receptors of rod bipolar cells are linked to a cyclic GMP cascade via G-Protein. Proc. R. Soc. Lond. B. Biol. Sci. 242:91-94, 1990.
23. Nawy, S., and Jahr, C.E. Suppression by glutamate of cGMP-activated conductance in retinal bipolar cells. Nature 346:269-271, 1990.
24. Dhingra, A., Lyubarsky, A., Jiang, M., et al. The light response of ON bipolar neurons requires G[alpha]o. J. Neurosci. 20:9053-9058, 2000.
25. Snellman, J., and Nawy, S. cGMP-dependent kinase regulates response sensitivity of the mouse on bipolar cell. J. Neurosci. 24:6621-6628, 2004.
26. Sandberg, M.A., Pawlyk, B.S., Crane, W.G., et al. Effects of IBMX on the ERG of the isolated perfused cat eye Vis. Res. 27:1421-1430, 1987.
27. Wallis, R.M., Casey, Y., Howe L., et al. Characterization of retinal phosphodiesterase (PDE) isoenzymes and the effects of sildenafil in vitro. Ophthalmic Res. 30:111, 1998.
28. Muirhead, G.J., Ranee, D.J., Walker, D.K., et al. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br. J. Clin. Pharmacol. 53:13-20, 2002.
29. Walker, D.A., Ackland, M.J., James, G.C., et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog, and man. Xenobiotica 29:297-310, 1999.
30. Muirhead, G.J., Wilner, K., Colburn, W., et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate. Br. J. Clin. Pharmacol. 53:21-30, 2002.
31. Muirhead, G.J., Faulkner, S., Harness, J.A., et al. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil healthy male Volunteers. Br. J. Clin. Pharmacol. 53:37-43, 2002.
32. Muirhead, G.J., Wulff, B., Fielding, A., et al. Pharmacokinetics interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. 50:99-107, 2000.
33. Walker, D.A., Ackland, M.J., James, G.C., et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog, and man. Xenobiotka 29:297-310, 2000.
34. Vobig, M.A., Klotz, T., Staak, M., et al. Retinal side-effects of sildenafil. Lancet 353:375, 1999.
35. Danciger, M., Blaney, J., Gao, Y.Q., et al. Mutations in the PDE 6B gene in autosomal recessive retinitis pigmentosa. Genomics 30:1-7, 1995.
36. Lolley, R.N., Farber, D.E., Rayborn, M.E., et al. Cyclic GMP accumulation causes degeneration of photore-ceptor cells: Simulation of an inherited disease. Science 196:664-666, 1977.
37. Gonzalez, C.M., Bervig, T., Podlasek, C., et al. Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina. Int. J. Impot. Res. 11:9-14, 1999.
38. Behn, D., and Potter, M.J. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. Invest. Ophthalmol. Vis. Sci. 42:523-527, 2001.